The U.S. Biomedical Advanced Research and Development Authority (BARDA) is partnering with Genentech, a subsidiary of Basel, Switzerland-based Roche Holding AG, to develop a portfolio of medical countermeasures (MCMs) that also have commercial uses. The partnership calls for BARDA to share development costs, have joint oversight, help determine which drugs to develop and collaborate on decisions about which products enter or leave the partnered portfolio.